双香豆乙酯 | 548-00-5

• 物质功能分类: 原料药 - 血液系统用药 - 抗凝血药及抗血小板药
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 中文名称: 双香豆乙酯
• 英文名称: ethyl biscoumacetate
• 英文别名: Ethylbiscoumacetat；stabilene；bis-(4-hydroxy-2-oxo-2H-chromen-3-yl)-acetic acid ethyl ester；Aethylbiscum-acetat (Bisoxycumarin-essigsaeureaethylester)；Ethylbiscum-acetat, Bisoxycumarin-essigsaeureethylester；Bis-3.3'-(4-hydroxycumarinyl)-essigsaeureaethylester；ethyl 2,2-bis(4-hydroxy-2-oxochromen-3-yl)acetate
• CAS: 548-00-5
• 化学式: C₂₂H₁₆O₈
• 分子量: 408.364
• InChiKey: JCLHQFUTFHUXNN-UHFFFAOYSA-N

物化性质

• 熔点：
  177-182° and mp 154-157°
• 沸点：
  448.92°C (rough estimate)
• 密度：
  1.3259 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  8

安全信息

• 危险等级：
  6.1(b)
• 海关编码：
  2932209090
• 危险品运输编号：
  UN 2811

制备方法与用途

类别：有毒物品

毒性分级：中毒

急性毒性：

• 口服 - 大鼠 LD50: 840 毫克/公斤
• 口服 - 小鼠 LD50: 750 毫克/公斤

可燃性危险特性：受热分解，产生刺激烟雾；药物副作用包括新血管系统异常、畸胎及死胎

储运特性：库房应通风、低温且干燥

灭火剂：干粉、泡沫、砂土、二氧化碳或雾状水

反应信息

• 作为反应物：
  描述：

  双香豆乙酯 在 吡啶 、 乙酸酐 作用下， 生成 6,8-dioxo-6H,7H,8H-pyrano[3,2-c;5,6-c'] dichromium ene-7-carboxylic acid ethyl ester
  参考文献：
  名称：

  Fucik et al., Bulletin de la Societe Chimique de France, 1949, p. 99,102

  摘要：

  DOI：
• 作为产物：
  描述：

  4-羟基-alpha-(4-羟基-2-氧代-2H-1-苯并吡喃-3-基)-2-氧代-2H-1-苯并吡喃-3-乙酸 、 乙醇 生成 双香豆乙酯
  参考文献：
  名称：

  INDRUCH, M.;GABRIFL, J.;DOSTAL, M.;MAYER, J.

  摘要：

  DOI：

文献信息

• GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS
  申请人：South Dakota Board of Regents

  公开号：US20200048305A1

  公开（公告）日：2020-02-13

  The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms of such compositions. In addition, methods for treating subjects by administering such compositions are also disclosed.

  本发明描述了含有胆固醇-连接剂-谷胱甘肽共轭物的组合物，通过克服血脑屏障（BBB）进入中枢神经系统的屏障入口，包括这些组合物的胶束和脂质体形式。此外，还公开了通过给予这些组合物治疗受试者的方法。
• Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
  申请人：Bezwada Rao S.

  公开号：US20120035259A1

  公开（公告）日：2012-02-09

  The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.

  本发明提供了一氧化氮(NO)和可选的药物释放的大分子和寡聚物，其中药物分子和一氧化氮释放部分通过可吸收的大分子或可水解降解的寡聚物链连接，并且大分子或寡聚物由来自诸如乙醇酸、乳酸、己内酰胺和对二恶烷等安全且生物相容的分子的重复单元组成。此外，本发明还涉及从一氧化氮和/或药物分子释放的大分子或寡聚物控制释放一氧化氮(NO)。此外，本发明还涉及包含本发明的一氧化氮和药物释放大分子和寡聚物的医疗器械、医疗器械涂层和治疗方法。
• ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES
  申请人：Bezwada Biomedical, LLC

  公开号：US20140142199A1

  公开（公告）日：2014-05-22

  The present invention relates to the discovery of a new class of hydrolysable isocyanates, hydrolysable branched polyols and branched absorbable polyesters and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, stents, highly porous foam, reticulated foam, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers can have a controlled hydrolytic degradation profile.

  本发明涉及一种新型可水解异氰酸酯、可水解支链多元醇及其制备的支链可吸收聚酯和聚氨酯的发现。由此得到的可吸收聚合物可用于药物输送、支架、高孔隙率泡沫、网状泡沫、组织工程、组织粘合剂、防止粘连、骨蜡制剂、医疗设备涂层、表面改性剂以及其他可植入医疗设备。此外，这些可吸收聚合物可以具有受控的水解降解特性。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• COATING FOR A MEDICAL DEVICE HAVING AN ANTI-THROMBOTIC CONJUGATE
  申请人：Zhao Jonathon Z.

  公开号：US20080200421A1

  公开（公告）日：2008-08-21

  A conjugate between an anti-thrombotic agent and a bioabsorbable polymer is provided. In addition, a method is provided for applying a coating comprising an anti-thrombotic agent and a bioabsorbable polymer conjugate to at least a portion of an implantable device to prevent or reduce the formation of thrombosis on the surface of the device. A first or sub-layer of the coating is prepared by mixing a polymeric material and a biologically active agent with a solvent, thereby forming a homogeneous solution. A second or outer layer comprises an anti-thrombotic heparin-bioabsorbable polymer conjugate. This coating may be applied over the inner drug-containing layers using, for example, a dip coating or spray coating process. After drying, the anti-thrombotic heparin bioabsorbable polymer conjugate remains in the outer layer of the coating, allowing agent from the inner layer to be eluted there through. In addition, the outmost layer prevents the formation of thrombosis, and also serves to modulate the release kinetics of the agent(s) contained within an inner layer(s) of the coating.

  提供了一种抗血栓药物与可生物吸收聚合物的共轭物。此外，提供了一种方法，用于将包含抗血栓药物和可生物吸收聚合物共轭物的涂层应用于可植入设备的至少部分表面，以预防或减少设备表面的血栓形成。涂层的第一或次表层通过将聚合物材料和生物活性剂与溶剂混合制备而成，从而形成均匀溶液。第二或外层包括抗血栓肝素-可生物吸收聚合物共轭物。该涂层可以通过浸涂或喷涂工艺覆盖在内部含药层上。干燥后，抗血栓肝素可生物吸收聚合物共轭物保留在涂层的外层，使内层的药物能够通过其释放。此外，最外层防止了血栓形成，并且还用于调节涂层内部层中所含药物的释放动力学。